Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.03Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -4.62%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong revenue growth, successful product expansions, and operational improvements. However, the impact of weather on testing volumes and the financial implications of the securities settlement present challenges.Company Guidance
During the CareDx first quarter 2025 earnings call, the company reiterated its 2025 guidance of $365 million to $375 million in revenue and an adjusted EBITDA gain between $29 million and $33 million. The first quarter reported revenue was $84.7 million, marking an 18% year-over-year increase, with a positive adjusted EBITDA of $4.6 million. Testing services generated $61.9 million, a 15% rise from the previous year, with a volume of approximately 47,100 tests, up 12%. CareDx ended the quarter with a cash balance of $231 million and no debt. Additionally, they launched two expanded indications for AlloSure and added 3.5 million new covered lives for AlloMap Heart and 15.5 million for AlloSure testing. The company also saw a 24% growth in patient and digital solutions revenue and a 26% growth in product revenue.Revenue and Growth Metrics
CareDx reported quarterly revenue of $84.7 million, up 18% year-over-year, and a positive adjusted EBITDA gain of $4.6 million. Testing services revenue was $61.9 million for the quarter, up 15% year-over-year.
Testing Volume Growth
The company achieved its seventh consecutive quarter of sequential testing volume growth, with approximately 47,100 tests conducted in the first quarter, up 12% from the prior year.
Product Launches and Expansions
CareDx launched two expanded indications for AlloSure testing, including AlloSure Heart for pediatric heart transplant patients under age seven and AlloSure Kidney for simultaneous pancreas kidney transplant patients.
Strong Cash Position
The company ended the quarter with a strong cash balance of $231 million and no debt.
Patient and Digital Solutions Growth
Revenue from patient and digital solutions was approximately $12 million in the first quarter, representing 24% year-over-year growth.
Operational Efficiency
Non-GAAP gross margin was 68.5%, up 150 basis points year-over-year, and the company reported an adjusted EBITDA gain compared to a loss in the same quarter last year.
---
CDNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CDNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $16.88 | $15.07 | -10.72% |
Feb 26, 2025 | $21.10 | $21.06 | -0.19% |
Nov 04, 2024 | $22.93 | $22.90 | -0.13% |
Jul 31, 2024 | $19.99 | $23.58 | +17.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CareDx (CDNA) report earnings?
CareDx (CDNA) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is CareDx (CDNA) earnings time?
CareDx (CDNA) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDNA EPS forecast?
CDNA EPS forecast for the fiscal quarter 2025 (Q2) is -0.1.
---
